Autopsy report · NCT01424501
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease
Cause of deathSafety
“Due to a safety signal found at a planned interim safety review, further conduct of this safety study is not recommended hence the study was terminated.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 2 years 5 months before it stopped.
- 142 participants enrolled.
- Results were posted on the registry 2 years 9 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Industry
- Conditions
- Tuberculosis
- Interventions
- GSK Biologicals' investigational TB vaccine GSK 692342; Placebo
- Participants
- 142
- Sites
- 6
- Countries
- Estonia, Taiwan
Trials that died the same way
- Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
“This study was terminated based on preliminary safety data.” - Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
“The study has been terminated due to a change in internal prioritization and not due to any safety concerns.” - A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
“The study terminated for safety reasons” - Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
“Study terminated based on evaluation of safety data.” - Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
“Study was terminated due to safety reason.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.